We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (“REIT”) earnings release this morning:
An In-Line FFO
Ventas came out with fourth-quarter 2016 adjusted normalized funds from operations (“FFO”) per share of $1.03, in-line with the Zacks Consensus Estimate.
How Was the Estimate Revision Trend?
Ventas has a decent earnings surprise history. Before posting an in-line results in Q4 results, the company delivered positive surprises in three of the trailing four quarters. On occasion, the company posted in-line results. Overall, the company surpassed the Zacks Consensus Estimate by an average of 1.48% in the trailing four quarters.
Ventas posted revenues of $875.7 million, which beat the Zacks Consensus Estimate of $843 million. Further, it compared favorably with the year-ago number of $841.3 million.
Key Developments to Note
Ventas expects its 2017 normalized FFO per share outlook in the range of $4.12 – $4.18.
The company anticipates same-store cash net operating income growth of 1.5–2.5% in 2017. Further, Ventas estimates 2017 dispositions of $900 million and intends to use the net proceeds from disposition for reinvestment for scaling the company’s life science and acute care hospital platforms and debt repayment.
Check back later for our full write up on this VTR earnings report later!
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks’ Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ventas' (VTR) Q4 FFO Meet Estimate; Revenues Beat
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q4 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (“REIT”) earnings release this morning:
An In-Line FFO
Ventas came out with fourth-quarter 2016 adjusted normalized funds from operations (“FFO”) per share of $1.03, in-line with the Zacks Consensus Estimate.
How Was the Estimate Revision Trend?
Ventas has a decent earnings surprise history. Before posting an in-line results in Q4 results, the company delivered positive surprises in three of the trailing four quarters. On occasion, the company posted in-line results. Overall, the company surpassed the Zacks Consensus Estimate by an average of 1.48% in the trailing four quarters.
Ventas, Inc. Price and EPS Surprise
Ventas, Inc. Price and EPS Surprise | Ventas, Inc. Quote
Revenue Came In Higher Than Expected
Ventas posted revenues of $875.7 million, which beat the Zacks Consensus Estimate of $843 million. Further, it compared favorably with the year-ago number of $841.3 million.
Key Developments to Note
Ventas expects its 2017 normalized FFO per share outlook in the range of $4.12 – $4.18.
The company anticipates same-store cash net operating income growth of 1.5–2.5% in 2017. Further, Ventas estimates 2017 dispositions of $900 million and intends to use the net proceeds from disposition for reinvestment for scaling the company’s life science and acute care hospital platforms and debt repayment.
What Zacks Rank Says
Ventas has a Zacks Rank #4 (Sell). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this VTR earnings report later!
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks’ Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>